Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease

Luciano Baronciani, Augusto B. Federici, Jeroen C J Eikenboom

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Type 3 von Willebrand disease (VWD) is the most severe form of this bleeding disorder owing to a virtually complete deficiency of von Willebrand factor (VWF). Type 3 VWD is inherited as a recessive trait-heterozygous relatives have mild or no bleeding symptoms, while most patients with type 3 VWD show severe bleeding because they are characterized by undetectable levels of VWF antigen and reduced concentrations (<0.10 IU/dL) of factor VIII. Although rare, type 3 VWD is of major interest because of its severe clinical presentation, the need for replacement therapy, and the risk of occurrence of alloantibodies after the infusion of plasma-derived VWF concentrates. The molecular basis of type 3 VWD has been studied in detail and numerous molecular defects have been identified. This chapter will focus on the clinical, laboratory, and molecular aspects of type 3 VWD that can be useful for a correct therapeutic approach in these patients.

Original languageEnglish
Title of host publicationVon Willebrand Disease: Basic and Clinical Aspects
PublisherWiley-Blackwell
Pages148-165
Number of pages18
ISBN (Print)9781405195126
DOIs
Publication statusPublished - Mar 21 2011

Fingerprint

Type 3 Von Willebrand's Disease
Biomarkers
von Willebrand Factor
Hemorrhage
Isoantibodies
Factor VIII
Therapeutics

Keywords

  • Alloantibodies
  • Bleeding symptoms
  • Laboratory tests
  • Molecular and prenatal diagnosis
  • Secondary long-term prophylaxis
  • Surgery
  • Type 3 von Willebrand disease
  • Von Willebrand factor
  • Von Willebrand factor concentrates

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Baronciani, L., Federici, A. B., & Eikenboom, J. C. J. (2011). Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease. In Von Willebrand Disease: Basic and Clinical Aspects (pp. 148-165). Wiley-Blackwell. https://doi.org/10.1002/9781444329926.ch13

Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease. / Baronciani, Luciano; Federici, Augusto B.; Eikenboom, Jeroen C J.

Von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell, 2011. p. 148-165.

Research output: Chapter in Book/Report/Conference proceedingChapter

Baronciani, L, Federici, AB & Eikenboom, JCJ 2011, Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease. in Von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell, pp. 148-165. https://doi.org/10.1002/9781444329926.ch13
Baronciani L, Federici AB, Eikenboom JCJ. Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease. In Von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell. 2011. p. 148-165 https://doi.org/10.1002/9781444329926.ch13
Baronciani, Luciano ; Federici, Augusto B. ; Eikenboom, Jeroen C J. / Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease. Von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell, 2011. pp. 148-165
@inbook{13f5c5615e8c431e8604472b62df4282,
title = "Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease",
abstract = "Type 3 von Willebrand disease (VWD) is the most severe form of this bleeding disorder owing to a virtually complete deficiency of von Willebrand factor (VWF). Type 3 VWD is inherited as a recessive trait-heterozygous relatives have mild or no bleeding symptoms, while most patients with type 3 VWD show severe bleeding because they are characterized by undetectable levels of VWF antigen and reduced concentrations (<0.10 IU/dL) of factor VIII. Although rare, type 3 VWD is of major interest because of its severe clinical presentation, the need for replacement therapy, and the risk of occurrence of alloantibodies after the infusion of plasma-derived VWF concentrates. The molecular basis of type 3 VWD has been studied in detail and numerous molecular defects have been identified. This chapter will focus on the clinical, laboratory, and molecular aspects of type 3 VWD that can be useful for a correct therapeutic approach in these patients.",
keywords = "Alloantibodies, Bleeding symptoms, Laboratory tests, Molecular and prenatal diagnosis, Secondary long-term prophylaxis, Surgery, Type 3 von Willebrand disease, Von Willebrand factor, Von Willebrand factor concentrates",
author = "Luciano Baronciani and Federici, {Augusto B.} and Eikenboom, {Jeroen C J}",
year = "2011",
month = "3",
day = "21",
doi = "10.1002/9781444329926.ch13",
language = "English",
isbn = "9781405195126",
pages = "148--165",
booktitle = "Von Willebrand Disease: Basic and Clinical Aspects",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease

AU - Baronciani, Luciano

AU - Federici, Augusto B.

AU - Eikenboom, Jeroen C J

PY - 2011/3/21

Y1 - 2011/3/21

N2 - Type 3 von Willebrand disease (VWD) is the most severe form of this bleeding disorder owing to a virtually complete deficiency of von Willebrand factor (VWF). Type 3 VWD is inherited as a recessive trait-heterozygous relatives have mild or no bleeding symptoms, while most patients with type 3 VWD show severe bleeding because they are characterized by undetectable levels of VWF antigen and reduced concentrations (<0.10 IU/dL) of factor VIII. Although rare, type 3 VWD is of major interest because of its severe clinical presentation, the need for replacement therapy, and the risk of occurrence of alloantibodies after the infusion of plasma-derived VWF concentrates. The molecular basis of type 3 VWD has been studied in detail and numerous molecular defects have been identified. This chapter will focus on the clinical, laboratory, and molecular aspects of type 3 VWD that can be useful for a correct therapeutic approach in these patients.

AB - Type 3 von Willebrand disease (VWD) is the most severe form of this bleeding disorder owing to a virtually complete deficiency of von Willebrand factor (VWF). Type 3 VWD is inherited as a recessive trait-heterozygous relatives have mild or no bleeding symptoms, while most patients with type 3 VWD show severe bleeding because they are characterized by undetectable levels of VWF antigen and reduced concentrations (<0.10 IU/dL) of factor VIII. Although rare, type 3 VWD is of major interest because of its severe clinical presentation, the need for replacement therapy, and the risk of occurrence of alloantibodies after the infusion of plasma-derived VWF concentrates. The molecular basis of type 3 VWD has been studied in detail and numerous molecular defects have been identified. This chapter will focus on the clinical, laboratory, and molecular aspects of type 3 VWD that can be useful for a correct therapeutic approach in these patients.

KW - Alloantibodies

KW - Bleeding symptoms

KW - Laboratory tests

KW - Molecular and prenatal diagnosis

KW - Secondary long-term prophylaxis

KW - Surgery

KW - Type 3 von Willebrand disease

KW - Von Willebrand factor

KW - Von Willebrand factor concentrates

UR - http://www.scopus.com/inward/record.url?scp=84865325226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865325226&partnerID=8YFLogxK

U2 - 10.1002/9781444329926.ch13

DO - 10.1002/9781444329926.ch13

M3 - Chapter

SN - 9781405195126

SP - 148

EP - 165

BT - Von Willebrand Disease: Basic and Clinical Aspects

PB - Wiley-Blackwell

ER -